GlycoMimetics to Continue Phase 3 Study of E-selectin Antagonist in Relapsed/Refractory AML

 

• Independent Data Monitoring Committee recommended pivotal Phase 3 study continue to the originally planned final overall survival events trigger and expressed no concerns about safety
• Interim utility analysis was conducted using a very high statistical threshold to preserve the integrity of the originally planned final analysis
• Review of blinded pooled data shows patients continue to live longer than historical benchmarks; final survival event trigger now expected within first half of 2024
• Company raised $32.9 million net proceeds via ATM facility, extending cash runway into Q4 2024

https://www.biospace.com/article/releases/glycomimetics-announces-continuation-of-phase-3-study-of-e-selectin-antagonist-uproleselan-in-relapsed-refractory-aml-to-originally-planned-final-analysis-following-interim-analysis-by-independent-data-monitoring-committee/